Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC

The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.

Related Keywords

Netherlands ,Merck Keytruda ,Myriam Chalabi ,Heather Wakelee ,Markm Awad ,Stanford University School Of Medicine ,Harvard Medical School ,Netherlands Cancer Institute ,Dana Farber Cancer Institute ,Stanford Cancer Institute ,New England Journal ,Stanford University School ,Stanford Cancer ,East Asian ,Dana Farber Cancer ,Netherlands Cancer ,Pembrolizumab ,Perioperative Pembrolizumab ,Nsclc ,Non Small Cell Lung Cancer ,Lung Cancer ,Keynote 671 ,New England Journal Of Medicine ,Asco Annual Meeting ,D ,Stanford ,